» Articles » PMID: 39125897

JAK Inhibitors in Rheumatoid Arthritis: Immunomodulatory Properties and Clinical Efficacy

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2024 Aug 10
PMID 39125897
Authors
Affiliations
Soon will be listed here.
Abstract

Rheumatoid arthritis (RA) is a highly prevalent autoimmune disorder. The pathogenesis of the disease is complex and involves various cellular populations, including fibroblast-like synoviocytes, macrophages, and T cells, among others. Identification of signalling pathways and molecules that actively contribute to the development of the disease is crucial to understanding the mechanisms involved in the chronic inflammatory environment present in affected joints. Recent studies have demonstrated that the Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway regulates the behaviour of immune cells and contributes to the progression of RA. Several JAK inhibitors, such as tofacitinib, baricitinib, upadacitinib, and filgocitinib, have been developed, and their efficacy and safety in patients with RA have been comprehensively investigated in a number of clinical trials. Consequently, JAK inhibitors have been approved and registered as a treatment for patients with RA. In this review, we discuss the involvement of JAK/STAT signalling in the pathogenesis of RA and summarise the potential beneficial effects of JAK inhibitors in cells implicated in the pathogenesis of the disease. Moreover, we present the most important phase 3 clinical trials that evaluated the use of these agents in patients.

Citing Articles

Mendelian randomization and mediation analysis reveal the role of immune cell subsets in the causal pathways between blood cell perturbation responses and rheumatoid arthritis.

Li F, Xian D, Yang K Clin Rheumatol. 2025; .

PMID: 40072781 DOI: 10.1007/s10067-025-07387-y.


METTL3-mediated methylation of RAC2 contributes to cell motility, oxidative stress and inflammation in TNF-α-stimulated rheumatoid arthritis fibroblast-like synovial cells.

Ren H, Wei G, Kong Z, Zhang M, Li Y, Liu S J Orthop Surg Res. 2025; 20(1):180.

PMID: 39980031 PMC: 11841323. DOI: 10.1186/s13018-025-05526-4.


Emerging Mechanisms and Biomarkers Associated with T-Cells and B-Cells in Autoimmune Disorders.

Sivalingam A Clin Rev Allergy Immunol. 2025; 68(1):14.

PMID: 39932617 DOI: 10.1007/s12016-025-09022-9.


The research progress of biologics in elderly-onset rheumatoid arthritis (EORA).

Li Y, Liu Y, Tian Y, Gu H, Meng Q, Cui J Front Aging. 2025; 5:1511812.

PMID: 39916724 PMC: 11798994. DOI: 10.3389/fragi.2024.1511812.

References
1.
Malemud C . The role of the JAK/STAT signal pathway in rheumatoid arthritis. Ther Adv Musculoskelet Dis. 2018; 10(5-6):117-127. PMC: 6009092. DOI: 10.1177/1759720X18776224. View

2.
Furuya M, Asano T, Sumichika Y, Sato S, Kobayashi H, Watanabe H . Tofacitinib inhibits granulocyte-macrophage colony-stimulating factor-induced NLRP3 inflammasome activation in human neutrophils. Arthritis Res Ther. 2018; 20(1):196. PMC: 6116484. DOI: 10.1186/s13075-018-1685-x. View

3.
Patel A, Bhatt V, Edara M . A Study of Haematological Profile in Newly Diagnosed Rheumatoid Arthritis and its Correlation with Disease Activity. J Assoc Physicians India. 2022; 70(4):11-12. View

4.
Liu H, Yang Y, Zhang J, Li X . Baricitinib improves pulmonary fibrosis in mice with rheumatoid arthritis-associated interstitial lung disease by inhibiting the Jak2/Stat3 signaling pathway. Adv Rheumatol. 2023; 63(1):45. DOI: 10.1186/s42358-023-00325-z. View

5.
Jose A, Samarpita S, Panchal N, Sabina E, Rasool M . Selective blockade of IL-21 by myricetin impedes T follicular helper cell differentiation by negatively regulating the JAK/STAT/Bcl-6 pathway in a rheumatoid arthritis animal model. 3 Biotech. 2024; 14(1):25. PMC: 10757705. DOI: 10.1007/s13205-023-03880-w. View